Skip to main content

Rational Drug Design of Selective Opioid Receptor Agonist TAN-821 and Antagonist TAN-1014

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

β-Endorphin (β-EP) is generally classified as aμ;andδ;opioid receptor agonist but is also an agonist of theopioid receptor. Although several selective agonists and antagonists for m, d, and k opioid receptors are known, selectivereceptor agonists or antagonists have not been reported for some time. Recently, we designed and synthesized the selectivereceptor agonist, 17-(cyclopropylmethyl)-4,5α-epoxy-3,6β- dihydroxy-6,14-endoethenomorphinan-7α-[N-methyl-N-phenethyl]carboxamide (TAN-821), and the selective e receptor antagonist, 17-(cyclopropylmethyl)-4,5α-epoxy-6b,21-epoxymethano-3-hydroxy-6,14-endoethenomorphinan- 7α-(N-phenethyl)carboxamide (TAN-1014). TAN-821 stimulated binding of the nonhydrolyzable guanosine 5'-triphosphate analogue, guanosine 5'-(γ-thio)-triphosphate (GTPgS), to the mouse pons/medulla membrane via activation of thereceptor. Moreover, TAN-821 given intracerebroventricularly (i.c.v.) produced marked, lonγ;lasting, and dose-dependent antinociception in tail-flick and hot-plate tests. This antinociception induced by i.c.v. administered TAN-821 was blocked by i.c.v. pretreatment with the e opioid receptor partial agonist β-EP (1-27), but not theμ;opioid receptor antagonist β-FNA, theδ;opioid receptor antagonist NTI, or the k opioid receptor antagonist nor-BNI. On the other hand, i.c.v. injection of TAN- 1014 alone produced no antinociception, and i.c.v. pretreatment with TAN-1014 attenuated the antinociception induced by i.c.v β-EP. These results suggest that TAN-821 and TAN-1014 are respectively a selectivereceptor agonist and antagonist and that they may be useful tools for investigating the pharmacological properties of theopioid receptor.

Keywords: TAN-1014; TAN-821; accessory site theory; analgesics; e opioid receptor; message-address concept; β-endorphin

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986706776360851

Affiliations: Pharmaceutical Research Laboratories, Toray Industries, Inc., 1111, Tebiro, Kamakura, Kanagawa, 248-8555, Japan.

Publication date: April 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2006/00000013/00000010/art00001
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more